Is remission of depressive symptoms in primary care a realistic goal? A meta-analysis

被引：22

作者：

Dawson M.Y. ^{[1
]}

Michalak E.E. ^{[1
]}

Waraich P. ^{[2
]}

Anderson J.E. ^{[3
]}

Lam R.W. ^{[1
]}

机构：

[1] Division of Clinical Neuroscience, Department of Psychiatry, University of British Columbia, Vancouver

[2] Division of Mental Health Services, Department of Psychiatry, Universityof British Columbia, Vancouver

[3] Sooke, BC V0S 1N0

来源：

BMC Family Practice | / 5卷 / 1期

关键词：

Major Depressive Disorder; Venlafaxine; Major Depressive Disorder; Primary Care Setting; Remission Rate;

D O I：

10.1186/1471-2296-5-19

中图分类号：

学科分类号：

摘要：

Background: A primary goal of acute treatment for depression is clinical remission of symptoms. Most meta-analyses of remission rates involve randomized controlled trials (RCTs) using patients from psychiatric settings, but most depressed patients are treated in primary care. The goal of this study was to determine remission rates obtained in RCTs of treatment interventions for Major Depressive Disorder (MDD) conducted in primary care settings. Methods: Potentially relevant studies were identified using computerized and manual search strategies up to May 2003. Criteria for inclusion included published RCTs with a clear definition of remission using established outcome measures. Results: A total of 13 studies (N = 3202 patients) meeting inclusion criteria were identified. Overall remission rates for active interventions ranged between 50% and 67%, compared to 32% for pill placebo conditions and 35% for usual care conditions. Conclusions: Remission rates in primary care studies of depression are at least as high as for those in psychiatric settings. It is a realistic goal for family physicians to target remission of symptoms as an optimal outcome for treatment of depression. © 2004 Dawson et al; licensee BioMed Central Ltd.

引用

共 43 条

[1]

Parikh S.V., Lam R.W., Clinical guidelines for the treatment of depressive disorders, I. Definitions, prevalence, and health burden, Can J Psychiatry, 46, 1 SUPPL., (2001)

[2]

Statistics Canada: Canadian Community Health Survey: Mental Health and Well-being

[3]

Desjardins B., Laurier C., The burden of depression in Canada, Value in Health, 5, (2002)

[4]

Murray C.J., Lopez A.D., Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study, Lancet, 349, pp. 1498-1504, (1997)

[5]

Hamilton M., Development of a rating scale for primary depressive illness, Br J Soc Clin Psych, 6, pp. 278-296, (1967)

[6]

Montgomery S.A., Asberg M., A new depression scale designed to be sensitive to change, Br J Psychiatry, 134, pp. 382-389, (1979)

[7]

Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush A.J., Weissman M.M., Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence, Arch Gen Psychiatry, 48, pp. 851-855, (1991)

[8]

Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., Keller M.B., Major depressive disorder: A prospective study of residual subthreshold depressive symptoms as predictor of rapid relapse, J Affect Disord, 50, pp. 97-108, (1998)

[9]

Judd L.L., Paulus M.J., Schettler P.J., Akiskal H.S., Endicott J., Leon A.C., Maser J.D., Mueller T., Solomon D.A., Keller M.B., Does incomplete recovery from first lifetime major depressive episode herald a chronic course of illness?, Am J Psychiatry, 157, pp. 1501-1504, (2000)

[10]

Judd L.L., Akiskal H.S., Maser J.D., Zeller P.J., Endicott J., Coryell W., Paulus M.P., Kunovac J.L., Leon A.C., Mueller T.I., Rice J.A., Keller M.B., A pro-spective 12-year study of subsyndromal and syndromal depressive symptoms in unipolar major depressive disorders, Arch Gen Psychiatry, 55, pp. 694-700, (1998)

← 1 2 3 4 5 →